NCT02054299

Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1

Effects of Genetic Polymorphisms in the Organic Cation Transporter OCT1 on Cellular Uptake and Metabolism of Antidepressants and Other Organic Cationic Drugs

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: University Medical Center Goettingen · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the effect of the organic cation transporter OCT1 polymorphisms on the pharmacokinetics of several drugs in order to explain efficacy and adverse effects.

Conditions

• Drug Metabolism
• Membrane Transport

Interventions

Type	Name	Description
DRUG	Drug application Amitriptyline	Amitriptyline: 25 mg, single oral application
DRUG	Drug application Desvenlafaxine	Desvenlafaxine: 50 mg, single oral application
DRUG	Drug application Sumatriptan	Sumatriptan: 50 mg, single oral application
DRUG	Drug application Proguanil	Proguanil: 200mg, single oral application
DRUG	Drug application Fenoterol	Fenoterol: 180 mcg, single intravenous application
DRUG	Drug application Thiamine	Thiamine: 200mg, single oral application

Timeline

• Start date: 2013-04-01
• Primary completion: 2016-02-01
• Completion: 2016-02-01
• First posted: 2014-02-04
• Last updated: 2016-05-12

Locations

1 site across 1 country: Germany